Paget Paget
Paget Paget
  Educational Slide Program  

Risedronate Sodium (Actonel )  
<< Back  
  This figure illustrates the percentage of patients who attained biochemical remission (serum alkaline phosphatase activity within the normal range) after receiving either 2 months of risedronate (30 mg/day) or 6 months of etidronate (400 mg/day). At the 6-month observation, 77% of risedronate-treated patients were in remission compared to 10% of etidronate-treated patients. In the follow-up period, extending 16 months after risedronate treatment was discontinued, 53% of patients were still in biochemical remission. Overall, 90% of the risedronate patients had not relapsed.  
    Previous Image | Next Image